US8580293 — Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
Method of Use · Assigned to Teva Womens Health Inc · Expires 2030-01-21 · 4y remaining
What this patent protects
This patent protects monolithic intravaginal rings containing progesterone, a specific type of vaginal ring used for a specific purpose.
USPTO Abstract
The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
Drugs covered by this patent
- Endometrin (progesterone) · Ferring
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2810 |
— | Endometrin |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.